CClinicalTrials.gg
CompletedNCT03521362Updated Apr 25, 2022

MyT1DHero: an mHealth Intervention for Type 1 Diabetes

An interventional study of MyT1DHero and Other T1D Mobile App in Type1diabetes, sponsored by Michigan State University. Completed at 1 site in United States. Open to participants aged 10 Years to 15 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Michigan State University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
10 Years to 15 Years
Sex
All
01

Study summary

The overall objective of the proposed research is to improve HbA1c, adherence to treatment plans, and family communication surrounding adolescents' self-management of T1D. The investigators will test the efficacy of the MyT1DHero app against an attention control group. This will allow investigators to better understand the health and psychosocial improvements being made through the app.

Read the detailed description

This research seeks to realize the potential and test the efficacy of MyT1DHero to improve adolescent users' glycemic control and adherence to blood glucose monitoring. The investigators' goal is to help families receive more social support, and to improve diabetes knowledge, self-efficacy, family communication, and quality of life. The investigators further seek to decrease family conflict among children with T1D and their parents. In a 12-month RCT, investigators will randomize 166 adolescents and their parents to one of two groups: (1) attention control, or (2) the MyT1DHero app. Adolescents enrolled in the study will be 10-15 years old, and will have been living with T1D for \<1 year or >5 years at the start of the study. The primary outcome will be a change in the participants' HbA1C from baseline levels at the start of the study, to levels measured after 12 months.

02

Conditions studied

  • Type1diabetes

Keywords

  • mHealth
  • Adolescent
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 33 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Michigan State University is the lead sponsor of 139 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The adolescents must:

    1. have a T1D diagnosis according to the ADA practice guidelines,
    2. be 10 to 15 years old,
    3. have had a diagnosis of T1D for at least six months,
    4. have an HbA1c > 7,
    5. have had at least two outpatient visits in the past two years,
    6. be treated at Spectrum for diabetes,
    7. be fluent in English,
    8. have a parent/guardian willing to participate,
    9. have and be allowed to use a mobile phone for the study, and
    10. have permission from their care team to participate.

The parent/guardian must:

  1. have an adolescent with T1D who is 10 to 15 years old,
  2. be fluent in English, and
  3. have daily access to email and the Internet (for appointment reminders and technical support).

Exclusion criteria

Exclusion Criteria:

  • For the adolescents include:

    1. significant medical conditions other than T1D,
    2. being treated for thyroid disorders, celiac disease, or eating disorders, and
    3. being in foster care.

Exclusion criteria for both the adolescents and parents/guardians include:

(a) a diagnosis of a major psychiatric or neurocognitive disorder (e.g., traumatic brain injury, dementia, schizophrenia, bipolar disorder, borderline personality disorder, and intellectual and developmental disabilities.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    MyT1DHero App

    Participants in this group will receive use of the MyT1DHero app.

    Device: MyT1DHero

  • Active comparator
    "Other" T1D App

    Participants in this group will receive use of a different app with less capabilities.

    Device: Other T1D Mobile App

Interventions

  • DeviceMyT1DHero

    MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.

  • DeviceOther T1D Mobile App

    A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Diabetes Behavior Rating Scale at 12 months

    A measure of diabetes adherence for both parent and child participants. Never (1) - Always(5) with a higher score indicating better adherence.

    Time frame: Baseline and 12 months

  2. Change from Baseline HbA1c at 6 months and 12 months

    A laboratory test that measures how high blood glucose has been on average over the last 8-12 weeks - for child participants only (Lower number is best)

    Time frame: Baseline, 6 months, and 12 months

Secondary outcomes

  1. Change from Baseline PROMIS Item Bank v2.0 - Informational Support - Short Form 6a at 12 months

    A measure of social support for the parent participants. Never (1) - Always (5), with a higher score indicating better support.

    Time frame: Baseline and 12 months

  2. Change from Baseline PROMIS Item Bank v2.0 - Emotional Support - Short Form 8a at 12 months

    A measure of social support for the parent participants. Never (1) - Always (5), with a higher score indicating more support.

    Time frame: Baseline and 12 months

  3. Change from Baseline NIH Toolbox Emotional Support (Ages 8-17) at 12 months

    A measure of social support for the child participants. Never (1) - Always (5), with a higher score indicating more support.

    Time frame: Baseline and 12 months

  4. Change from Baseline Diabetes Empowerment Scale Short Form at 12 months

    A measure of diabetes-related self-efficacy for both parent and child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more empowerment.

    Time frame: Baseline and 12 months

  5. Change from Baseline PROMIS® Item Bank v.1.0 - General Self-Efficacy at 12 months

    A measure of self-efficacy for the parent participants. I am not at all confident (1) - I am very confident (5), with a higher score indicating higher self-efficacy.

    Time frame: Baseline and 12 months

  6. Change from Baseline NIH Toolbox Self-efficacy (ages 8-12) at 12 months

    A measure of self-efficacy for the child participants. Never (1) - Very often (5), with a higher score indicating higher self-efficacy.

    Time frame: Baseline and 12 months

  7. Change from Baseline Confidence in Diabetes Self-Care (Psychometric properties of a new measure of diabetes-specific self-efficacy in Dutch and U.S. patients with type 1 diabetes) at 12 months

    A measure of diabetes-related self-efficacy for the child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more confidence in self-care ability.

    Time frame: Baseline and 12 months

  8. Change from Baseline PROMIS® Item Bank v1.0 - General Life Satisfaction - Short Form 5a at 12 months

    A measure of quality of life for the parent participants. Strongly disagree (1) - Strongly agree (7), with a higher score indicating more life satisfaction.

    Time frame: Baseline and 12 months

  9. Change from Baseline PedsQL (Measurement Model for the Pediatric Quality of Life Inventory) at 12 months

    A measure of quality of life for the child participants. Never (0) - Almost Always (4), with a lower score indicating better quality of life.

    Time frame: Baseline and 12 months

  10. Change from Baseline Neuro-QOL Item Bank v1.0 -Pediatric Stigma - Short Form at 12 months

    A measure of stigma for the child participants. Never (1) - Always (5), with a higher score indicating more feelings of stigma.

    Time frame: Baseline and 12 months

  11. Change from Baseline Diabetes Conflict Scale at 12 months

    A measure of conflict for both the parent and child participants. Almost Always (1) - Never (3), with a higher score indicating less conflict.

    Time frame: Baseline and 12 months

  12. Change from Baseline PROMIS® Parent Proxy Item Bank v1.0 - Family Relationships - Short Form 8a at 12 months

    A measure of family characteristics for both the parent and child participants. Never (1) - Always (4), with a higher score indicating better family relationships.

    Time frame: Baseline and 12 months

  13. Change from Baseline Diabetes Family Behavior Scale at 12 months

    A measure of family characteristics for both the parent and child participants. All of the time (1) - Never (5), with a lower score indicating better family behavior.

    Time frame: Baseline and 12 months

  14. Change from Baseline Family Functioning Scale at 12 months

    A measure of family characteristics for both the parent and child participants. Totally disagree (1) - Totally agree (6). Responses are summed. Subscales include intimacy (items 1, 4, 6, 10, 13, 15, 18, 20, 23, 26, 27, 29), conflict (items 3, 5, 8, 9, 12, 14, 17, 19, 22, 24), and parenting style (items 2, 7, 11, 16, 21, 25, 28, 30).

    Time frame: Baseline and 12 months

  15. Change from Baseline Impact on Family (Construct: Parental perceptions of the impact of a child's medical condition on the family) at 12 months

    A measure of family characteristics for the parent participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more impact (burden).

    Time frame: Baseline and 12 months

  16. Change from Baseline Family Satisfaction (FSS) at 12 months

    A measure of family characteristics for the parent participants. Very dissatisfied (1) - Extremely satisfied (5), with a higher score indicating more satisfaction.

    Time frame: Baseline and 12 months

  17. Change from Baseline Neuro-QOL Item Bank v1.0 -Anxiety - Short Form at 12 months

    A measure of anxiety for the parent participants. Never (1) - Always (5), with a higher score indicating more anxiety.

    Time frame: Baseline and 12 months

  18. Change from Baseline Neuro-QOL Item Bank v1.0 -Pediatric Anxiety - Short Form at 12 months

    A measure of anxiety for the child participants. Never (1) - Almost always (5), with a higher score indicating more anxiety; Not at all (1) - Very much (5); with a higher score indicating more anxiety.

    Time frame: Baseline and 12 months

  19. Change from Baseline Short-Form Outcome Expectations at 12 months

    A measure of diabetes outcome expectancy for both the parent and child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more positive outcome expectations

    Time frame: Baseline and 12 months

  20. Usability and Satisfaction Questionnaire

    A measure of technology usability and satisfaction for both the parent and child participants

    Time frame: 12 months

  21. Unified theory of acceptance and use of technology (UTAUT) Vantakesh, Morris, et al., 2003

    A measure of technology usability and satisfaction for both the parent and child participants

    Time frame: 12 months

07

Study locations

1 site
  • Michigan State University
    East Lansing, Michigan 48823, United States
08

References and documents

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03521362
Lead sponsor
Michigan State University
Collaborators
Spectrum Health Hospitals, American Diabetes Association
Responsible party
Bree Holtz (Assistant Professor, Michigan State University) — Principal investigator
First posted
May 11, 2018
Start date
Jan 1, 2019
Primary completion
Dec 1, 2021
Completion
Dec 1, 2021
Last update
Apr 25, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion